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Copyright © 200? JCBN Summary The standardised Ginkgo biloba extract EGb761 is known for its potential beneficial
effects in the prevention and therapy of neurodegenerative disorders including Alzheimer’s
disease (AD). However, the molecular mechanisms and the specific role of its constituents are
largely unknown. The aim of the present feeding trial was to investigate the effects of EGb761
and its major constituents on the expression of genes encoding for proteins involved in the
pathogenesis of AD in mouse brain. Six month old C57B6 mice were fed semi synthetic diets
enriched with either EGb761 or one of its main fractions, flavonols and terpenelactones,
respectively, over a period of 4 weeks. Thereafter, mRNA of α-secretase, neprilysin, amyloid
precursor protein (App), App binding protein-1 and acetylcholine esterase was quantified in
hippocampus and cortex. EGb761 and its flavonol fraction had no effects on relative mRNA
levels of the respective genes in mouse brain. However, the terpenelactone fraction signifi-
cantly decreased the mRNA levels of App in the hippocampus. Taken together, a 4 week
dietary treatment with EGb761 or its main fractions had only moderate effects on mRNA
levels of AD related genes in cortex and hippocampus of mice.
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Introduction
EGb761 is an extract from the leaves of the Ginkgo biloba
tree and standardised by its two main groups of constituents,
the flavonols (22–27%) and terpenelactones (5–7%) [1]
(Fig. 1). The extract is widely administered for the preven-
tion and therapy of disturbances in vigilance, memory,
cognitive functions and dementias including Alzheimer’s
disease (AD) [2, 3]. Both, the flavonols and terpenelactones
are thought to be, at least partly, responsible for the pharma-
cological activity of EGb761 [4]. However, the molecular
mechanisms involved and the specific role of the respective
constituents are largely unknown. Bastianetto and co-
workers have shown a protective effect of EGb761 and its
flavonol fraction against nitric oxide induced toxicity in
hippocampal cells whereas the terpenelactone fraction failed
to exhibit any effect [5]. In a study with neuronal PC12 cells,
the Ginkgo biloba terpenelactone bilobalide diminished the
cytotoxic effects of Amyloid β (Aβ) fragments that play a
decisive role in AD pathology [6,  7]. Other studies also
found evidence that the terpenelactone fraction of EGb761
might be more relevant for the neuroprotective activities of
the extract [7–10]. A gene array study suggested that theS. Augustin et al.
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gene-regulatory activity of Ginkgo biloba on gene expres-
sion in the brain could be involved in its neuroprotective
activity [11]. A study by Watanabe et al. showed that in
cortex and hippocampus of mice fed a diet supplemented
with EGb761 several genes were up regulated, among them
genes encoding for transthyretin (Ttr), prolactin and growth
hormone [11]. These genes could be molecular targets of
EGb761 in improving neurological and cognitive functions
[7, 11–13]. However, it is still unclear which compounds of
EGb761 are responsible for this effect. Thus, in the present
study we investigated the effect of diets supplemented with
EGb761 or with its flavonol and terpenelactone fractions on
the mRNA levels of genes involved in the pathogenesis of
AD in mice. Due to their prominent role in AD pathology,
especially genes involved in amyloid-precursor protein
(App) metabolism were analysed. These include App itself,
a protease that cleaves APP (Adam10), the Aβ-degrading
protease neprilysin (Nep), and App binding protein 1
(Appbp1), a protein that induces apoptosis and is increased
in human AD brains [14–17]. Acetylcholine esterase (Ache)
mRNA levels were also investigated because increasing the
synaptic acetylcholine concentration by inhibiting Ache
enzyme activity is one of the current strategies in AD
therapy [18].
Materials and Methods
Source of extracts
Three different extracts of Ginkgo biloba leaves were
used in the present study: the standardised Ginkgo biloba
extract EGb761 and two extracts containing either the
flavonol or the terpenelactone fraction of EGb761, respec-
tively (Table 1). All extracts were a kind gift from Dr.
Schwabe pharmaceuticals (Karlsruhe, Germany).
Animals
Eighty female C57B6 mice aged 6 months (Charles River
Breeding Laboratories, Sulzfeld, Germany) were randomly
allocated to four dietary groups (n = 20 each, body weight
24.5 ± 1.2 g; means ± SEM). Five mice per cage were
housed and maintained under standard conditions (23 ± 1°C,
55% relative humidity, 14 h light/10 h dark cycle). The mice
were fed a commercial semi-synthetic low-flavonoid diet
(C1000 code #100E, Altromin; Lage, Germany) enriched
either with no extract (control diet, C), with 300 mg
EGb761/kg diet (G), 300 mg flavonol extract/kg diet (F) or
100 mg terpenelactone extract/kg diet (T). Prior to the
dietary intervention, mice were adapted to the control diet
for one week. The animals had ad libitum access to the diets
and tap water. Body weights were recorded weekly.
Fig. 1. Structure of the main flavonolsquercetin (A), isorhamnetin (B) and kaempferol (C) and the main terpenelactones, the
ginkgolides (D) and bilobalide (E), present in EGb761 and its main fractions used (according to [1]).Gene Regulatory Effects of EGb761 and Its Main Fractions
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After 4 weeks on the experimental diets, mice were
euthanatized and blood was collected in heparinised tubes
(Sarstedt, Nuembrecht, Germany). Blood samples were taken
from all animals per dietary group (n = 20) and pooled group-
wise. Brain cortices and hippocampi for PCR analyses were
rapidly dissected, immediately suspended in RNAlaterTM
RNA stabilisation reagent (Qiagen, Hilden, Gemany) and
incubated over night. Hippocampus tissue samples of all
animals per cage were pooled. RNA sample preparation
was performed as previously described [19]. RNA integrity
was checked by denaturating agarose gel electrophoresis
and ethidium bromide staining. Total RNA (0.5 μg per lane)
was separated on a 2% agarose gel (agarose neeo, Carl
Roth, Karlsruhe, Germany). Total RNA degradation was
evaluated from the ratio between 18S to 28S rRNA peak areas
quantified with the ChemiDoc XRS using QuantityOneTM
software (version 4.6.5; BioRad Laboratories, Munich,
Germany). A ratio of 0.5 ± 0.075 was accepted.
Animal care and experimental procedures were conducted
according to the German Guidelines and Regulation on
Animal Care (Deutsches Tierschutzgesetz, 2006) and were
approved by the University of Kiel Committee on Animal
Care.
Determination of flavonoid and terpenelactone content in
plasma
Plasma was obtained after centrifugation (2000 × g for
10 min, 4°C) and stored at −80°C until analysis. Flavonols
were analysed in plasma aliquots by HPLC with postcolumn
derivatisation as described previously [20]. Plasma samples
were treated with β-glucuronidase/sulfatase (Carl Roth)
prior to extraction of flavonols.
Terpenelactones were analysed by Dr. Schwabe pharma-
ceuticals. Plasma aliquots were acidified with HCl (0.1N)
and analysed using a GC/MS method according to Fourtallin
and Biber & Koch with minor modifications [21, 22].
Determination of mRNA levels
Primer pairs for target genes were designed to the corre-
sponding sequence of Mus musculus mRNA sequences
using primer3 software (http://fokker.wi.mit.edu/primer3/
input.htm). Primer sequences are provided in Table 2. Primer
pairs were obtained from MWG (Ebersberg, Germany).
QuantiTectTM Primer Assay (Qiagen) was used for 18S
rRNA amplification, with a product of 149 bp. One-step
quantitative reverse transcriptase polymerase chain reaction
(One-Step qRT-PCR) was performed as previously described
by Augustin [19]. All runs were performed at an annealing
temperature of 55°C (Adam10: 58°C). Quantification and
melting curves of the amplified PCR products were analysed
using the RotorGene3000TM software (Corbett Lifescience,
Sydney, Australia). Data was normalized by dividing the
expression level of each target gene by the level of 18S rRNA.
Immunoblotting
Hippocampi for protein analysis were pooled per cage,
immediately frozen in liquid nitrogen and stored at −80°C
until analysis. For isolation of membrane-bound proteins
Radio Immuno Precipitation Assay (RIPA)-lysis-buffer
(150 mM sodium chloride, 1.0% NP-40, 0.5% sodium
Table 1. Amount of flavonols, ginkgolides and bilobalide in the
used extract EGb761 (G) and in two extract fractions
containing either its flavonols (F) or terpenelactones (T)
*Data provided by Schwabe pharmaceuticals (Karlsruhe, Germany).
Data is shown as % w/w to the whole extract. #not determined.
†n.d.: not detectable.
GFT
Amount (% w/w)*
∑ Flavonols 24.4 25 #
Quercetin 10.9 # 0.19
Kaempferol 11.2 # 0.18
Isorhamnetin 2.3 # n.d.†
∑ Terpenoids 6 <1 38.27
Bilobalide 3.02 # 21.44
Ginkgolid A 1.28 # 6.35
Ginkgolid B 0.55 # 3.76
Ginkgolid C 1.15 # 6.72
Table 2. Nucleotide sequences of PCR primers used in real-time qRT-PCR
target gene and mRNA sequence sense antisense product
Ache (acetylcholine esterase); NM_009599 ccaccgatcctctggacgag cgctcctgcttgctatagtg 112 bp
Adam10 (a disintegrin and metallopeptidase 10); 
NM_007399
ccatgctcatggaagacagtt ccttcttcaccataaatatgtcca 144 bp
App (amyloid beta precursor protein); NM_007471.2 ccgttgcctagttggtgagt gctcttctcgctgcatgtc 142 bp
Appbp1 (amyloid beta precursor binding protein 1); 
NM_144931.2
gctgccaggtattggatcat gctcggttcttgccaatact 108 bp
Nep (neprilysin), NM_008604 cattttgaccagcctcgact ggcaaactttgttcctgacg 137 bp
Ttr (transthyretin); NM_013697 ggaagacacttggcattcc tctctcaattctgggggttg 153 bpS. Augustin et al.
J. Clin. Biochem. Nutr.
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deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) containing
protease-inhibitors (Complete Mini, Roche, Mannheim,
Germany) was used. Tissue samples (25 ± 5m g )  w e r e
homogenized in RIPA-buffer (200 μl per 5 mg) with a rotor-
stator homogenizer for 45 s, agitated for 2 h at 4°C, and
centrifuged (20 min, 15300 × g, 4°C). The supernatant was
removed and the protein amount was measured with the
BCA kit (Pierce Biotechnology, Rockford, IL). Protein
homogenates were diluted 1:1 with Laemmli sample buffer
(BioRad Laboratories) containing 5% β-mercaptoethanol
and denaturated for 5 min at 95°C. Electrophoresis was
performed on 10% Tris-HCl gel (15 μg protein per lane;
Criterion Gel System, BioRad) and proteins were transferred
onto Immobilion P-PVDF membranes (Millipore, Bedford,
MA). Membranes were blocked in 3% non-fat milk (Biomol,
Hamburg, Germany) in Tris-buffered saline containing 0.5%
Tween 20 (TBST) at room temperature for 6 h. Subsequently,
blots were incubated with the primary antibodies for 12 h
at room temperature followed by incubation with horse-
radish peroxidase-conjugated secondary antibodies (1:10000;
Abcam, Cambridge, UK) for 1 h at room temperature. The
following primary antibodies were used: monoclonal anti-
APP (clone 22C11; 1:2000; Chemicon, Temecula, CA), and
rabbit polyclonal anti-actin as internal control (1:2000;
Abcam). All antibodies were diluted in TBST. Immuno-
detection analyses were performed with the ImmunStarTM
WesternC Kit (BioRad). All quantitative analyses were
performed with the ChemiDoc XRS using QuantityOneTM
software (version 4.6.5; BioRad).
Statistical analysis
Statistical calculations were conducted with Graphpad
Prism 4 software (Graphpad Software Inc., San Diego, CA).
Data of target gene mRNA levels were analysed by one-way
ANOVA followed by Dunnetts multiple comparison test for
pair wise comparison of group means. Data of target protein
levels were analysed by non parametric Mann-Whitney-U
test. Data are presented as mean ± SEM, and significance
was accepted at p<0.05. Plasma flavonoid and terpenoid
concentrations were not statistically analysed since pooled
plasma samples were used.
Results
Plasma concentration of flavonols and terpenelactones
In plasma of control mice, concentrations of the main
Ginkgo flavonols quercetin, kaempferol, and isorhamnetin
were 0.069 μmol/l, 0.037 μmol/l and 0.005 μmol/l,
respectively. The respective concentrations for quercetin,
kaempferol and isorhamnetin in mice treated with either
EGb761 or its flavonol fraction were 0.108 μmol/l,
0.121 μmol/l, and 0.108 μmol/l (EGb761) or 0.075 μmol/l,
0.080 μmol/l, and 0.098 μmol/l (flavonol fraction), respec-
tively. Thus, in both treatment groups the total concentration
of flavonols was increased more than twofold compared to
controls. In contrast, mice treated with the terpenelactone
fraction had similar plasma flavonol levels as control animals
(0.073 μmol/l, 0.056 μmol/l, and 0.009 μmol/l for quercetin,
kaempferol, and isorhamnetin, respectively).
Plasma concentrations of the terpenelactones ginkgolide
A, ginkgolide B, and bilobalide were below the limit of
detection (<0.02 μmol/L plasma) in control mice and in
mice treated with the flavonol fraction. In contrast, animals
that had received either EGb761 or its terpenelactone frac-
tion had terpenoid concentrations in plasma that were clearly
above the detection limit (in mice treated with EGb761:
0.07 μmol/l bilobalide, 0.396 μmol/l ginkgolide A and
0.164 μmol/l ginkgolide B; in mice treated with terpene-
lactones: 0.235 μmol/l bilobalide, 0.429 μmol/l ginkgolide
A and 0.291 μmol/l ginkgolide B).
mRNA levels of Alzheimer’s Disease relevant genes
The mRNA levels of the housekeeping gene 18S rRNA
were not significantly different between the different treat-
ments (data not shown). Neither EGb761 nor its flavonol
fraction significantly affected the mRNA levels of the inves-
tigated target genes in mouse cortex (Table 3). In cortex of
mice treated with the terpenelactone fraction, the expression
of Ttr was increased, but this was not significant, probably
due to the high inter-individual variation. Furthermore, other
genes investigated including Ache, Adam10, Appbp1 and
Nep were not significantly affected by the terpenelactone
fraction. The increase in Nep mRNA level by ~50% in the
EGb761 group was also not significant (Table 3).
In hippocampus, neither EGb761 nor its flavonol fraction
affected the mRNA level of App (Table 4). In contrast,
App expression in hippocampi of mice treated with the
terpenelactone fraction was significantly lower than in
control animals. However, EGb761 and both of its fractions
failed to alter mRNA expression of Ache, Adam10, Appbp1,
Nep or Ttr significantly (Table 4). In accordance with
cortex, EGb761 seemed to increase Nep mRNA levels in
hippocampus; however, this was also not significant.
Interestingly, mRNA levels of Ttr relative to 18S rRNAwere
50–200 fold higher in hippocampus compared to cortex
(data not shown).
Protein levels of amyloid precursor orotein
Since the terpenelactone fraction significantly down-
regulated App mRNA levels in the hippocampus, protein
levels of App was also analysed by Western blotting. In
accordance with the mRNA data, terpenelactone fraction
also decreased the protein expression of App by ~20% in
hippocampus compared to control animals, but this was not
significant (data not shown).Gene Regulatory Effects of EGb761 and Its Main Fractions
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Discussion
The present study examined the effects of the Ginkgo
biloba extract EGb761 and its flavonol and terpenelactone
fractions on brain mRNA levels of genes involved in the
pathogenesis of AD. Adult C57B6 mice were treated over a
period of 4 weeks with diets enriched with either the whole
extract, or with its flavonol or terpenelactone fraction. The
increase in plasma flavonol and/or terpenelactone concen-
trations in the respective dietary groups demonstrated the
absorption of these constituents from the diets. This finding
is in accordance with previous data from humans [21] and
laboratory animals [22, 23].
It is still largely unknown if and to what extent EGb761
constituents may cross the blood-brain barrier. De Boer et al.
could detect quercetin, a major constituent of EGb761, in
brain tissue of rats [24]. This indicates absorption and
distribution of at least some of the major constituents of
EGb761 to the brain. EGb761 has been shown to inhibit
generation of Aβ from APP and Aβ aggregation, which are
crucial processes in AD pathogenesis [25–27]. Furthermore,
App protein levels in cortex and hippocampus were decreased
in rats after oral treatment with Ginkgo biloba extract for 28
weeks [28]. In the present study, neither dietary EGb761 nor
its flavonol fraction affected App mRNA levels in cortex
and hippocampus after 4 weeks of treatment. The different
outcome between the two studies may be explained by the
different duration of the dietary treatment (4 vs 28 weeks)
and/or by species differences (rat vs mice). However, dietary
treatment with the terpenelactone fraction led also in our
study to a significant decrease in App mRNA, at least in
hippocampus. Several studies reported that in particular
the terpenelactones could be the most relevant constituents
with regard to the neuroprotective properties of EGb761
[6–10]. In this context, Ahlemeyer and Kriegelstein analysed
data from in vitro and in vivo studies regarding potential
beneficial effects of EGb761; they concluded that the
terpenelactones including ginkgolide B and bilobalide may
be the most effective constituents of EGb761 against oxida-
tive damage in the brain [9]. It has to be taken into account
that in our study the active ingredients in the terpenelactone
enriched diet were twofold higher compared to the EGb761
enriched diet (Table 1). Thus, EGb761 could be equally
effective as the terpenelactone fraction when higher doses
of EGb761 are administered.
mRNA levels of other genes apart from App, including
Ache, Adam10, Appbp1 and Nep, were not significantly
altered by EGb761 or by its main fractions after 4 weeks of
dietary treatment in our study. However, we found a slight
but non significant increase in hippocampus Ttr mRNA
levels in the EGb761 group. Furthermore, the diet supple-
mented with terpenelactones increased also mRNA levels of
Table 3. Relative mRNA levels of AD relevant genes in the cortex of mice fed either a control diet or a diet enriched with
EGb761 or with its flavonol or terpenelactone fraction over a period of 4 weeks.
Data are expressed as mean ± SEM and are relative to control. C, control; G, EGb761; F, flavonol fraction; T, terpenelactone
fraction; n = 10 in each group.
target gene C G F T
Ache 1.00 ± 0.13 0.73 ± 0.06 0.83 ± 0.10 0.79 ± 0.06
Adam10 1.00 ± 0.05 0.94 ± 0.03 1.11 ± 0.05 1.01 ± 0.03
App 1.00 ± 0.03 0.98 ± 0.05 1.00 ± 0.06 1.03 ± 0.03
Appbp1 1.00 ± 0.04 1.02 ± 0.07 1.02 ± 0.06 1.00 ± 0.03
Nep 1.00 ± 0.14 1.53 ± 0.25 1.22 ± 0.25 1.19 ± 0.18
Ttr 1.00 ± 0.40 0.54 ± 0.23 0.85 ± 0.38 2.4 ± 0.76
Table 4. Relative mRNA levels of AD relevant genes in the hippocampus of mice fed either a control diet or a diet enriched
with EGb761 or with its flavonol or terpenelactone fraction over a period of 4 weeks.
Data are expressed as mean ± SEM and are relative to control. C, control; G, EGb761; F, flavonol fraction; T, terpenelactone
fraction; n =4 ;  * p<0.05.
target gene C G F T
Ache 1.00 ± 0.09 1.06 ± 0.14 1.36 ± 0.10 1.18 ± 0.12
Adam10 1.00 ± 0.05 1.00 ± 0.05 0.97 ± 0.05 0.90 ± 0.10
App 1.00 ± 0.06 0.88 ± 0.06 0.82 ± 0.06 0.73 ± 0.07*
Appbp1 1.00 ± 0.11 1.18 ± 0.10 1.18 ± 0.12 0.94 ± 0.05
Nep 1.00 ± 0.18 1.72 ± 0.39 1.05 ± 0.16 1.21 ± 0.28
Ttr 1.00 ± 0.32 1.64 ± 0.72 1.22 ± 0.40 1.16 ± 0.50S. Augustin et al.
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Ttr in cortex, although this was not significant again. Several
studies demonstrate a potential beneficial effect of tran-
sthyretin against Aβ toxicity and plaque formation in murine
models for AD [29–32]. It has also been shown that brains of
AD patients have decreased levels of transthyretin [32]. In a
previous study, Watanabe et al. observed a significant
increase in Ttr mRNA levels in hippocampus after a 4 week
dietary treatment with EGb761 [11]. Our results cannot fully
support this latter observation. Interestingly, Sousa et al.
have shown that Ttr mRNA might exclusively occur in the
choroids plexus [33]. These authors generated tissue
samples via micro dissection and detected Ttr mRNA
neither in the cortex nor in the hippocampus of wild-type
mice and transgenic mice models of AD. They stated that the
reason for the detection of Ttr mRNA in other brain tissues
such as cortex and hippocampus could only be due to tissue
contamination [33]. Thus, the high variation in Ttr mRNA
levels in cortex and hippocampus in our study could be due
to a possible contamination of theses samples with choroid
plexus. This could also explain the difference between our
data and that of Watanabe et al. [11]. Thus, further studies
are warranted to reveal the impact of EGb761 on Ttr expres-
sion especially in the choroid plexus.
Regarding the time dependency of the development of any
effects of EGb761 within the brain, a definitive statement is
not possible. On the one hand, Watanabe et al. [11] have
shown that EGb761 significantly influences gene expression
in brains of adult mice after 4 weeks of dietary treatment,
whereby most of the affected genes were associated with
neuroprotective properties (e.g. growth hormone or τ-
protein). On the other hand, we have also recently shown in
a transgenic mouse model for AD (Tg2576 mice) that only
long-term treatment (16 months, old mice) decreased App
mRNA and protein levels; in the same trial, a 4 week
treatment (young mice) did not affect mRNA levels of genes
investigated [19,  34]. This study, however, indicates that
not only the duration of the treatment with Ginkgo biloba,
but also the (biological) age of the animals might influence
results. In this context, a study by Williams et al. has shown
an age-related effect of a short-term treatment with EGb761
(30 days) on synaptic plasticity and excitability. Only in old
mice (aged 18–24 months) the beneficial effects of EGb761
on investigated parameters were significant. The authors
mentioned that the absence of effects of EGb761 in young
mice (aged 2–3 months) may indicate that EGb761’s
influence is only expressed in a system where normal
homeostatic processes are undergoing age-related decline
and where an increase in the range of synaptic plasticity
could prove beneficial [35]. Thus, further studies are
required to elucidate the possible age-related and/or time-
dependent effects of EGb761 on gene expression.
Taken together, our results indicate that a 4 week dietary
treatment with EGb761 or its flavonol and terpenelactone
fractions induces only moderate effects on the expression of
genes relevant for Alzheimer disease in healthy mice.
However, terpenelactones seem to be able to decrease the
expression of amyloid precursor protein. This could lead to
a reduced generation of the neurotoxic Aβ. To test this
hypothesis, long-term studies in aged mice are warranted to
investigate the effect of terpenelactones on Aβ generation
and clearance in a mouse model for AD.
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